DEVELOPMENT AND EVALUATION OF METFORMIN HCL LOADED EUDRAGIT®RSPO AND EUDRAGIT®RLPO AND GLIMEPIRIDE BILAYER TABLETS

The present study was carried out for developing the formulation of Bilayer tablets of Glimepiride, Metformin HCl. Immediate Release (IR) layer was compressed as direct compression method and Sustained Release (SR) layer blends were compressed by wet granulation method. IR and SR layers were evaluated for pre and post compression studies and all studies were found to be within limits. From dissolution data of Glimepiride Immediate release layer, IR5 formulation was shown maximum drug release at 60 min i.e., 96.4%. Hence IR5was concluded as optimised formulation for IR layer. Sustained layer consists the drug Metformin HCl From the dissolution data of bilayer tablets of Anti Diabetic drugs F4 (IR5&SR4) has shown optimum drug release,SR4 contains Eudragit RL100 Polymer.SR4 formulation was shown best drug release(95.57%)within 24 hours. Finally SR4 formulation was optimised formulation and follows Higuchi release kinetics. Key Words: Glimepiride, Metformin HCl, Bilayer tablets, direct compression, wet granulation, Ethyl Cellulose, Eudragit RL100, PVP K30.